Keyword: Merck & Co.

News

MSD to Acquire EyeBio for up to $3 Billion

29.05.2024 -

US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).

News

MSD Animal Health to Acquire Elanco’s Aqua Business

07.02.2024 -

MSD Animal Health, a division of Merck & Co., announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for €1...

News

Merck & Co. to Acquire Harpoon Therapeutics for $680 Million

09.01.2024 -

US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity...

News

Merck & Co. to Acquire Caraway Therapeutics

22.11.2023 -

Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total...

News

Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide

20.10.2023 -

Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where...

News

Astex and MSD Expand Drug Discovery Collaboration

15.08.2023 -

UK-based Astex Pharmaceuticals, specialized in the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system...

News

US Merck Fails to Transfer all Talc Liability to Bayer

14.04.2023 -

A move by US drugmaker Merck & Co. to have Bayer assume all liability for lawsuits alleging that the talc-based Dr. Scholl's foot powder causes cancer has failed, at...

News

Proxygen and US Merck Collaborate on Molecular Glue Degraders

12.04.2023 -

Austrian biotech Proxygen has announced a multi-year collaboration and license agreement with US drugmaker Merck & Co to identify and develop molecular glue degraders...